Microsimulation model of the cost-effectiveness of anifrolumab compared to belimumab in the United Arab Emirates

References

• Shaikh MF, Jordan N, D'Cruz DP. Systemic lupus erythematosus. Clin Med. 2017;17(1):78–83. doi: 10.7861/clinmedicine.17-1-78.
   PubMed Web of Science ®Google Scholar
• Justiz Vaillant AA, Goyal A, Varacallo M. Systemic lupus erythematosus. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. https://www.ncbi.nlm.nih.gov/books/NBK535405/
   Google Scholar
• Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ. 2013;16(5):667–677. doi: 10.3111/13696998.2013.778270.
   PubMedGoogle Scholar
• Li T, Carls GS, Panopalis P, et al. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum. 2009;61(6):755–763. doi: 10.1002/art.24545.
   PubMedGoogle Scholar
• Kan HJ, Song X, Johnson BH, et al. Healthcare utilization and costs of systemic lupus erythematosus in medicaid. Biomed Res Int. 2013;2013:808391–808398. doi: 10.1155/2013/808391.
   PubMed Web of Science ®Google Scholar
• Al Dhanhani AM, Agarwal M, Othman YS, et al. Incidence and prevalence of systemic lupus erythematosus among the native Arab population in UAE. Lupus. 2017;26(6):664–669. doi: 10.1177/0961203316678677.
   PubMed Web of Science ®Google Scholar
• Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356. doi: 10.1136/ard-2022-223035.
   PubMed Web of Science ®Google Scholar
• Özsungur F. The psychological effects of systemic lupus erythematosus: the imitator of aging. LymphoSign J. 2020;7(1):37–45. doi: 10.14785/lymphosign-2019-0016.
   Google Scholar
• Al Sawah S, Daly RP, Foster SA, et al. The caregiver burden in lupus: findings from UNVEIL, a national online lupus survey in the United States. Lupus. 2017;26(1):54–61. doi: 10.1177/0961203316651743.
   PubMed Web of Science ®Google Scholar
• Carls G, Li T, Panopalis P, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009;51(1):66–79. doi: 10.1097/JOM.0b013e31818a405a.
   PubMed Web of Science ®Google Scholar
• Grabich S, Farrelly E, Ortmann R, et al. Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the medical expenditure panel survey (MEPS) 2016-2018. Lupus Sci Med. 2022;9(1):e000640. doi: 10.1136/lupus-2021-000640.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Bonsmann G, Anders HJ, et al. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int. 2015;112(25):423–432. doi: 10.3238/arztebl.2015.0423.
   PubMed Web of Science ®Google Scholar
• Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. Mediterr J Rheumatol. 2017;28(1):4–12. doi: 10.31138/mjr.28.1.4.
   PubMedGoogle Scholar
• Katz P, Nelson WW, Daly RP, et al. Patient-Reported lupus flare symptoms are associated with worsened patient outcomes and increased economic burden. J Manag Care Spec Pharm. 2020;26(3):275–283. doi: 10.18553/jmcp.2020.26.3.275.
   PubMed Web of Science ®Google Scholar
• Bell CF, Ajmera MR, Meyers J. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. Lupus. 2022;31(2):202–211. doi: 10.1177/09612033211073670.
   PubMed Web of Science ®Google Scholar
• Teh CL, Ling GR. Causes and predictors of mortality in hospitalized lupus patient in Sarawak general hospital, Malaysia. Lupus. 2013;22(1):106–111. doi: 10.1177/0961203312465780.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Wilson K, Ogelsby A, et al. Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States. J Occup Environ Med. 2013;55(11):1262–1270. doi: 10.1097/JOM.0000000000000008.
   PubMed Web of Science ®Google Scholar
• Felten R, Sagez F, Gavand PE, et al. 10 Most important contemporary challenges in the management of SLE. Lupus Sci Med. 2019;6(1):e000303. doi: 10.1136/lupus-2018-000303.
   PubMed Web of Science ®Google Scholar
• Emamikia S, Gentline C, Enman Y, et al. How can We enhance adherence to medications in patients with systemic lupus erythematosus? Results from a qualitative study. J Clin Med. 2022;11(7):1857. doi: 10.3390/jcm11071857.
   PubMed Web of Science ®Google Scholar
• Golder V, Kandane-Rathnayake R, Hoi AY, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19(1):62. doi: 10.1186/s13075-017-1256-6.
   PubMedGoogle Scholar
• Morand EF, Abreu G, Furie RA, et al. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis. 2023;82(5):639–645. doi: 10.1136/ard-2022-222748.
   PubMed Web of Science ®Google Scholar
• Zucchi D, Cardelli C, Elefante E, et al. Treat-to-target in systemic lupus erythematosus: reality or pipe dream. J Clin Med. 2023;12(9):3348. doi: 10.3390/jcm12093348.
   PubMed Web of Science ®Google Scholar
• SAPHNELO. Highlights of prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf
   Google Scholar
• SAPHNELO. Product monograph. 2023. https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/saphnelo-product-monograph-en.pdf.
   Google Scholar
• Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019; 1 (4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1.
   PubMedGoogle Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi: 10.1056/NEJMoa1912196.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-Interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(2):376–386. doi: 10.1002/art.39962.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250. doi: 10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi: 10.1016/S0140-6736(10)61354-2.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi: 10.1002/art.30613.
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-Blind, placebo-Controlled study. Arthritis Rheumatol. 2017;69(5):1016–1027. doi: 10.1002/art.40049.
   PubMed Web of Science ®Google Scholar
• CADTH Reimbursement Review. Anifrolumab. 2023. https://www.cadth.ca/sites/default/files/DRR/2023/SR0717-Saphnelo_combined.pdf.
   Google Scholar
• Watson P, Brennan A, Birch H, et al. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. Rheumatology. 2015;54(4):623–632. doi: 10.1093/rheumatology/keu375.
   PubMed Web of Science ®Google Scholar
• Thanou A, Chakravarty E, James JA, et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci Med. 2014;1(1):e000005. doi: 10.1136/lupus-2013-000005.
   PubMedGoogle Scholar
• Furie R, Morand EF, Bruce IN, et al. What does it mean to be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment responder? Post hoc analysis of two phase III trials. Arthritis Rheumatol. 2021;73(11):2059–2068. doi: 10.1002/art.41778.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014;73(1):183–190. doi: 10.1136/annrheumdis-2012-202760.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health observatory data repository, life table, UAE. 2023. https://apps.who.int/gho/data/view.main.LT62250
   Google Scholar
• Bruce IN, Golam S, Steenkamp J, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022;11(10):765–777. doi: 10.2217/cer-2022-0040.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, et al. (2012). Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Med Decis Making. 2012;32(5):667–677. doi: 10.1177/0272989X12454577.
   PubMed Web of Science ®Google Scholar
• Chirikov VV, Walker C, Stephens JM, et al. Evaluating the cost-effectiveness of celecoxib versus ibuprofen and naproxen in patients with osteoarthritis in United Arab Emirates based on the PRECISION trial. Clinicoecon Outcomes Res. 2021;13:409–420. doi: 10.2147/CEOR.S280556.
   PubMed Web of Science ®Google Scholar
• BENLYSTA. Highlights of prescribing information. 2023. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF
   Google Scholar
• BENLYSTA. Product monograph. 2023. https://ca.gsk.com/media/6151/benlysta.pdf
   Google Scholar
• BENLYSTA. Summary of product characteristics. 2023. https://www.ema.europa.eu/en/documents/product-information/benlysta-epar-product-information_en.pdf
   Google Scholar
• Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 2023;75(2):253–265. doi: 10.1002/art.42392.
   PubMed Web of Science ®Google Scholar
• The World Bank. GDP per capita (current LCU) - United Arab Emirates. 2023. https://data.worldbank.org/indicator/NY.GDP.PCAP.CN?locations=AE
   Google Scholar
• Bell CF, Huang SP, Cyhaniuk A, et al. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus. 2023;32(2):301–309. doi: 10.1177/09612033221146093.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Dall Era M, Aranow C, et al. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13:980079. doi: 10.3389/fimmu.2022.980079.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins lupus cohort. Lupus Sci Med. 2015;2(1):e000066–e000066. doi: 10.1136/lupus-2014-000066.
   PubMed Web of Science ®Google Scholar
• Bruce IN, van Vollenhoven RF, Psachoulia K, et al. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trialsLupus. Lupus Sci Med. 2023;10(1):e000761. doi: 10.1136/lupus-2022-000761.
   PubMed Web of Science ®Google Scholar
• Hao Y, Oon S, Ji L, et al. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. Clin Rheumatol. 2022;41(2):357–366. doi: 10.1007/s10067-021-05940-z.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967. doi: 10.1136/annrheumdis-2013-205139.
   PubMed Web of Science ®Google Scholar
• Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol. 2018;70(11):1790–1795. doi: 10.1002/art.40571.
   PubMed Web of Science ®Google Scholar
• Sharma C, Raymond W, Eilertsen G, et al. Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. Arthritis Care Res. 2020;72(3):447–451. doi: 10.1002/acr.23867.
   PubMed Web of Science ®Google Scholar
• Yeo AL, Koelmeyer R, Kandane-Rathnayake R, et al. Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus. Arthritis Care Res. 2020;72(9):1289–1295. doi: 10.1002/acr.24023.
   PubMed Web of Science ®Google Scholar
• Anifrolumab (Saphnelo). CADTH reimbursement recommendation. 2023. https://canjhealthtechnol.ca/index.php/cjht/article/view/SR0717/1197
   Google Scholar
• Stull D, O'Quinn S, Williams B, et al. Causal Cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two phase 3 trials. Rheumatology. 2022;61(12):4731–4740. doi: 10.1093/rheumatology/keac138.
   PubMed Web of Science ®Google Scholar